Form 4: Zeo ScientifiX Chief Medical Officer Granted Stock Options

Dr. George Craig Shapiro, Chief Medical Officer of Zeo ScientifiX, Inc., was granted stock options for 125,000 shares on July 11, 2024.

Summary

• On July 11, 2024, George Craig Shapiro, the Chief Medical Officer of Zeo ScientifiX, Inc. (ZEOX), was granted stock options for 125,000 shares.
• The options have an exercise price of $2.35.
• The options vest in equal monthly installments over 18 months, starting August 11, 2024, and expire on July 11, 2034.
• These options were granted under the company's 2021 Equity Incentive Plan.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard executive compensation practice, neither particularly positive nor negative on its own.

Positives

• The grant of stock options aligns the Chief Medical Officer's interests with those of the shareholders, incentivizing performance and company growth.

Industry Context

Stock option grants are a common practice in the biotechnology and pharmaceutical industries to attract and retain key personnel, aligning their interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Amgen, Gilead, and Biogen routinely use stock options to incentivize their leadership teams.
• The vesting schedule of 18 months is fairly typical, as it encourages long-term commitment from the executive.
• The exercise price of $2.35 would need to be compared to the current market price of ZEOX to determine the potential value to the recipient.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the Chief Medical Officer to drive company success.
• Employees may see this as a positive sign of investment in leadership.

Key Dates